drugset
drugset / Trial / NCT00398840

A Study of ARQ 171 in Patients With Advanced Solid Tumors

NCT00398840 ↗

Phase 1 Terminated 14 enrolled ArQule, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.

Timeline

Start
2006-11
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ARQ 171 Unknown — Intravenous

Indications

cancer